Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial

Fig. 1

VICTOR trial schema VICTOR trial schema showing the patient pathway highlighting treatment decisions depending on disease status. #, cycles; CR, complete remission/response; DA, daunorubicin; DAGO, daunorubicin, cytarabine and gemtuzumab ozogamicin; FLAG-IDA, fludarabine, cytarabine and idarubicin; HIDAC, high-dose cytarabine; LDAC, low-dose cytarabine; MRD, minimal residual disease; R, randomisation; VEN, venetoclax

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us